Condition

Post-Acute COVID-19 Syndrome

ClinicalTrials.gov condition label

Clinical trials5

Recruiting3

Common interventions5

Lead sponsors shown5

Clinical trials

5 shown

IMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 ConditionNCT07197138 · 2025-09-11

A Study of Apabetalone in Subjects With Long -COVIDNCT06590324 · 2025-04-15

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation ResearchNCT04806620 · 2023-07-05

REVERSE-Long COVID-19 With Baricitinib StudyNCT05858515 · 2024-10-21

Acute Metabolic Outcomes in Diabetic Patients Hospitalized for COVID-19 (DMD-COV)NCT07560059 · 2021-01-28

Common interventions

ApabetaloneDRUG1 Baricitinib 4 MGDRUG1 Intermittent theta-burst stimulation (iTBS) using PowerMAG 100 ppTMSDEVICE1 No intervention (observational study)OTHER1 PlaceboDRUG1

Leading sponsors

Algerian Society of Diabetology1 Brain Inflammation Collaborative1 Max-Planck-Institute of Psychiatry1 Resverlogix Corp1 Vanderbilt University Medical Center1

Trial status mix

RECRUITING3

COMPLETED1

WITHDRAWN1

Phase mix

PHASE32

NA1

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.